PIRS Pieris Pharmaceuticals Inc.

4.29
0  0%
Previous Close 4.29
Open
Price To Book 7.03
Market Cap 211,331,908
Shares 49,261,517
Volume 305
Short Ratio
Av. Daily Volume 443,242

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data presented at EHA June 16, 2019.
PRS-080
Anemia of chronic disease
Phase 1 initial data presented May 22, 2019 - well tolerated, supports further development.
PRS-060
Asthma
Phase 1 data due 2019.
PRS-343
HER2-positive solid tumors
Phase 1 data due 2019.
PRS-343 and atezolizumab (Tecentriq)
HER2-positive solid tumors

Latest News

  1. These 4 Charts Are Looking Better And Better
  2. Implied Volatility Surging for Pieris Pharmaceuticals (PIRS) Stock Options
  3. Pieris Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
  4. Pieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the American Thoracic Society (ATS) 2019 International Conference
  5. Edited Transcript of PIRS earnings conference call or presentation 10-May-19 12:00pm GMT
  6. Pieris Pharmaceuticals to Present at the 2019 RBC Capital Markets Global Healthcare Conference
  7. Pieris Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
  8. Pieris Pharmaceuticals to Host First Quarter 2019 Investor Call and Corporate Update on May 10, 2019
  9. Analysts Estimate Pieris Pharmaceuticals (PIRS) to Report a Decline in Earnings: What to Look Out for
  10. Did You Miss Pieris Pharmaceuticals's (NASDAQ:PIRS) 56% Share Price Gain?
  11. Pieris Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
  12. Pieris Pharmaceuticals Presents Preclinical Data for GPC3/4-1BB Bispecific PRS-342 at the 2019 American Association for Cancer Research (AACR) Annual Meeting
  13. Edited Transcript of PIRS earnings conference call or presentation 12-Mar-19 12:00pm GMT
  14. Pieris Pharmaceuticals Reports 2018 Year-End Cash Position and Provides Corporate Update
  15. Pieris Pharmaceuticals, Inc. to Host Earnings Call
  16. Pieris Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
  17. Pieris Pharmaceuticals to Host Full-Year 2018 Investor Call and Corporate Update on March 12, 2019
  18. Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A — New Research Emphasizes Economic Growth
  19. Does Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Have A Particularly Volatile Share Price?
  20. What Kind Of Shareholder Appears On The Pieris Pharmaceuticals, Inc.’s (NASDAQ:PIRS) Shareholder Register?